Therefore, a novel, quantitative, facile, low-cost test that would complement dopamine transporter imaging and could be administered prior to radiotracer injection may be valuable for the objective assessment of motor dysfunction in early PD. This evidence concerns the gene SLC6A3 and Parkinson disease.